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Abstract
Gene therapy has been proposed for many diseases in the nervous system. In most cases for successful treatment,
therapeutic vectors must be able to transduce mature neurons. However, both in vivo, and in vitro, where preliminary
characterisation of viral particles takes place, transduction of neurons is typically inefficient. One possible explanation is that
the extracellular matrix (ECM), forming dense perineural nets (PNNs) around neurons, physically blocks access to the cell
surface. We asked whether co-administration of lentiviral vectors with an enzyme that disrupts the ECM could improve
transduction efficiency. Using hyaluronidase, an enzyme which degrades hyaluronic acid, a high molecular weight molecule
of the ECM with mainly a scaffolding function, we show that in vitro in mixed primary cortical cultures, and also in vivo in rat
cortex, hyaluronidase co-administration increased the percentage of transduced mature, NeuN-positive neurons. Moreover,
hyaluronidase was effective at doses that showed no toxicity in vitro based on propidium iodide staining of treated cultures.
Our data suggest that limited efficacy of neuronal transduction is partly due to PNNs surrounding neurons, and further that
co-applying hyaluronidase may benefit applications where efficient transduction of neurons in vitro or in vivo is required.
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Introduction
In order to understand how different genes can modify specific
neuronal functions, it is necessary to manipulate gene expression
in neurons. However, reliably introducing genetic material into
neurons has been problematic (for review see [1]). Recently
lentiviral vectors have emerged as a powerful tool capable of
delivering DNA to neurons in vitro and in vivo. While the trans-
duction efficiency with viral vectors in general is largely dependent
on titre, further limitations of the ability to transduce cells are
imposed, in vivo mainly through the restricted diffusion of
lentivector particles around the injection site within the extracel-
lular matrix of the brain [2], and in vitro, especially for lower
multiplicities of infection (MOIs), through an as yet poorly
understood restriction. In many studies this is circumvented by
transducing at early time points or simultaneously with seeding
cells [3,4,5,6,7,8,9,10]. In general transduction efficiency is
thought to decrease with increasing age of the neuronal culture
(days in vitro; DIV) but few groups have systematically investigated
this. In cases where virally transduced genes are intended to take
effect in mature neurons only, or where transduced genes may
disrupt development and differentiation of plated neurons, the
requirement to transduce neurons in vitro at early stages in order to
achieve high transduction efficiency presents a major drawback.
One possibility is that the age-related decrease in transduction
efficiency is linked to the maturation of neuronal cells, with
changes of the outer cellular surface during this phase restricting
viral entry into cells. All types of cells are surrounded by
extracellular matrix (ECM), and one of the main constituents of
the ECM is hyaluronic acid (HA), a long polysaccharide
molecule which is composed of N-acetyl-glucosamine and D-
glucuronic acid [11,12]. HA is anchored to extracellular
receptor CD44 and CD168 [13] and serves as a scaffold to
keep proteins and molecules that support cellular viability in
close proximity to the cell surface (for review see [14]). The
importance of HA in the brain has been recognised since the
1970s [15,16]. It entirely covers neurons, including cell bodies,
dendrites and axons [17], and in conjunction with other
molecules such as chondroitin sulphate proteoglycan and various
proteins like tenascins, reelin, laminin, HA is central to building
up a net like structure surrounding neurons, known as
perineural nets (PNNs). In the brain, HA is thought to maintain
the physicochemical properties of the ECM [18,19], but there is
increasing evidence that HA also alters functional properties of
neurons [20,21,22]: The characteristic distribution of HA and
changes during cerebral development are indicative of function-
al properties (n.b. there is no HA in the adult cerebellum);
neurite growth is altered by HA, and neurites tend to avoid HA
containing collagen substrates. HA can also have an impact on
membrane potential, as indicated by the depolarization
observed when HA was added to cultured neurons [23]. The
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mechanisms of these interactions are still a matter of
speculation, but could be related to altered distribution of
extracellular ions or signalling via CD44 receptors. Recently HA
has been shown to influence neurotransmission and signalling,
and also to contribute to synaptic plasticity by regulating use-
dependent Ca2+ currents via Cav1.2 channels [24], thus
manipulation of HA might have consequences for neuronal
viability. Hyaluronidase is an enzyme which cleaves HA, and
could be used to degrade the PNNs and increase access to the
surface of neurons.
We report that treating cells with hyaluronidase improves
transduction efficiency with lentiviral vectors in vitro and in vivo.
This was done after evaluating potential toxic effects in vitro and
in vivo on neuronal survival.
Materials and Methods
All experimental procedures of this study involving animals
were carried out in accordance with the UK Animals (Scientific
Procedures) Act 1986 and following ethical approval from UCL
Institute of Neurology.
Chemicals if not specified are from Sigma (St. Louis, Missouri,
USA).
Production of Lentiviral Vectors and Titration
Second and third generation lentiviral vectors have been
produced as described previously [25,26]. Both express different
GFP variants driven by different promoters, with pGIPZ (second
generation; Open Biosystems, ThermoScientific, Waltham, Mas-
sachusetts, USA) expressing turboGFP (tGFP) under the control of
CMV promoter, and pCDH1-MCS1-EF1-copGFP (third gener-
ation; System Biosciences, Mountain View, California, USA)
expressing copGFP under the EF1a promoter. Packaging was
done with plasmids pCMVDR8.91 for second generation vector
[27], or pMDLg/pRRE and pRSV-Rev [26] for third generation
vectors, together with the vesicular stomatitis virus protein G
envelope plasmid pMD2.G expressing VSV-G surface protein for
both (packaging and envelope plasmids were kindly provided by
D. Trono, Geneva, Switzerland). To make vectors, the corre-
sponding plasmids were co-transfected with calcium phosphate
method into HEK293T cells (originally form ATCC/LGC
Standards, Teddington, UK), which were cultured in DMEM
(PAA, Pasching, Austria) supplemented with 10% FBS (Gibco-
Invitrogen, Carlsbad, California, USA) and Penicillin/Streptomy-
cin (PAA) in a 5%-CO2 incubator (Binder, Tuttlingen, Germany)
at 37uC in a humidified atmosphere. Supernatant has been
collected 48 and 72 hours after transfection, concentrated with
ultracentrifugation (Kontron Instruments, Zuerich, Switzerland) in
a SW28.1 rotor (Beckman, Brea, California, USA) and resus-
pended in 50 ml DMEM medium without any additives. Titration
was carried out separately for each vector in HEK293T cells by
transducing them with serial dilutions of concentrated vector using
polybrene (8 mg/ml; Sigma). The percentage of green cells was
analysed with a FACS Calibur flow cytometer (Becton Dickinson,
Franklin Lakes, New Jersey, USA) 72 h after transduction. The
viral dilutions which gave 1–10% green cells have been chosen to
calculate titres, which were in the range between 1 * 108 and 2 *
109 TU/ml. As the different vectors relied upon distinct
promoters, the calculated titres may partly reflect different
reporter expression levels in HEK cells. For this reason, all
comparisons of viral efficacy were done using a single virus,
however to show that the influence of ECM on transduction level
was not restricted to a single promoter we carried out similar tests
on more than one vector.
Rat Primary Mixed Cortical Cultures
Sprague Dawley rat pups (P0–P1; UCL breeding colony, UCL,
London, UK) were used for primary mixed cultures. The protocol
was a slightly modified version of [28]. Cortex of both hemispheres
was removed, purified and minced in HBSS. Trypsin (PAA) was
added to a final concentration of 0.25%. After incubation at 37uC
for 15 min, cortical pieces were triturated with fire-polished
Pasteur pipettes. 105 cells were seeded on 13 mm coverslips
(Menzel glass, Braunschweig, Germany), which were pre-treated
with Poly D-Lysin/Laminin (Sigma). They were cultivated in 12-
well plates in a total volume of 1.5 ml complete Neurobasal-A
medium (Neurobasal-A, supplemented with B-27(R) serum-free
supplement and Glutamax; all Invitrogen), and kept at 37uC in
a humidified atmosphere CO2-incubator (5% CO2, Binder). A
partial medium change (one third of the total volume) to maintain
the cultures was scheduled twice per week.
Hyaluronidase Treatment and Lentiviral Transduction of
Rat Primary Neuronal Cultures
Hyaluronidase from bovine testes Type I-S (Sigma) was diluted
in complete Neurobasal-A medium as a 3-fold concentrated stock
solution, which was done freshly on the day of the experiment.
After adding hyaluronidase to the medium it was left on the cells
without subsequent medium change (partial medium change was
scheduled according to regular maintenance; there were at least
two days between experimental treatment and medium change).
For transductions, different vector batches were used after
correction for differences in their titres. In order to achieve
a multiplicity of infection MOI=1 in a well with 105 cells plated,
105 TU per well were added. Scaling up to higher MOIs was
accomplished accordingly.
Transfection of Neuronal Cultures
For transfection of neuronal cultures in the 12-well format
(105 cells per well), Lipofectamine2000TM (Invitrogen) was used
according to the manufacturer’s instructions. Two different
amounts of DNA were used, with the higher amount being
1.6 mg of pCDH1-MCS1-EF1-copGFP DNA and 4 ml Lipofecta-
mine2000TM reagent in 100 ml OptiMEMH (Invitrogen) each, or
the lower amount with 0.8 mg of pCDH1-MCS1-EF1-copGFP
DNA and 2 ml Lipofectamine2000TM reagent in 50 ml Opti-
MEMH each.
Immunocytochemistry
For immunostaining of transduced neurons in vitro, primary
neuronal cells grown on a coverslip were fixed in 4% para-
formaldehyde/PBS, permeabilized with 0.1% Triton/PBS and
subsequently blocked in 1% BSA/0.2% Tween20/PBS. Mouse
anti-rat NeuN antibody (1:400; clone A60, Millipore, Billerica,
Massachusetts USA) was used to stain neuron-specific NeuN
antigen. Rabbit Anti-turboGFP antibody (1:1000; AB513, Cam-
bridge Biosciences, Cambridge, UK) was used to stain tGFP and
copGFP. Primary antibodies were diluted in 1% BSA/0.2%
Tween20/PBS. The corresponding secondary antibodies were
Alexa fluor 594TM goat anti-mouse (1:400, A11005, Invitrogen)
and DyLight 488TM goat anti-rabbit (1:400, 35553, Thermo
Scientific), respectively. Cells were mounted on to microscopic
slides using Vectashield antifade mounting medium (Vecta
Laboratories, Burlingame, California, USA).
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Intracerebral Injections of Lentiviral Vectors and/or
Hyaluronidase
Eight male Sprague-Dawley rats (11 weeks; Harlan, Shardlow,
UK) were used for these experiments. They were kept in the local
animal facilities at the Institute of Neurology, with a 12-h light/
dark cycle and with ad libitum access to food and water. For
stereotactic surgery they were deeply anaesthetised with Vetflur-
ane (Virbac, Suffolk, UK), and fixed to a stereotactic frame (Kopf
Instruments, Tujunga, California, USA). Two holes were drilled
into the skull at the targeted injection area in the motor cortex.
The coordinates were 1.0 mm anterior to Bregma, 2.4 mm
laterally from midline, 2.0 mm underneath the surface of the
skull. Injections were done with a 33G injection cannula of a 5 ml
Hamilton syringe, attached to an automated injection device
(WPI, Sarasota, Florida, USA) promoting the injection at a rate of
200 nl/min over a period of 10 min per site. The total injection
volume was 2 ml per site. The cannula was left in place for 5 min
after each injection. After removal the skin was sutured and
disinfected with Braunoderm (Braun-Melsungen, Melsungen,
Germany). Postoperative care included analgesia injection of
Buprenorphine (BuprenexH, Reckitt Benckiser, Slough, UK). The
animals were maintained to allow vector genes 12 days to express
prior to brain removal.
The injection solution was a mixture of 1 ml the lentiviral vector
(pCDH1-MCS1-EF1-copGFP, titre 2 * 109 TU/ml) and either
1 ml PBS or 1 ml hyaluronidase in PBS (4 or 20 U/ml). This
resulted in an injection of 106 TU of lentiviral vector in 2 ml, with
or without 4 or 20 U hyaluronidase. Each animal received both
treatments, with PBS or hyaluronidase in either of the two
hemispheres. Injections of hyaluronidase only contained the final
amount of enzyme (4 or 20 U) in 2 ml volume PBS.
Immunohistochemistry
Animals were transcardially perfused with PBS and 4% PFA in
PBS. Brains were removed and fixed overnight in 4% PFA. 50 mm
free floating coronal sections were cut on a vibratome (VT1000S,
Leica, Wetzlar, Germany) and kept at 4uC in PBS until further
use.
Brain slices were permeabilized with 0.3% Triton/PBS, and
subsequently blocked in 1% BSA/0.3% Triton/PBS. The same
primary (for NeuN and tGFP) and corresponding secondary
antibodies were used with the same dilutions as described for
Immunocytochemistry. They were diluted in 1% BSA/0.3%
Triton/PBS. Stained brain slices were mounted onto microscopic
slides and sealed with PVA mounting medium (Sigma).
For staining of the extracellular matrix (see [29]), the slices were
incubated in biotinylated Wisteria floribunda agglutinin (20 mg/ml;
Sigma) in PBS overnight at 4uC. After washing (3610 min in
PBS), slices were incubated in Strepdavidin-Texas Red (5 mg/ml;
Invitrogen) for 2 h and washed 3610 min in PBS afterwards.
Nuclear staining was done with 5 mM Hoechst 33342 (Molecular
Probes, Eugene, Oregon, USA), slices were mounted onto
microscopic slides and sealed with PVA mounting medium
(Sigma).
Fluoro-Jade C staining was done as previously described [30].
Briefly, sections were mounted onto microscopic slides and
incubated in 0.06% KMnO4 for 10 min. After washing
(262 min in H2O), they were incubated in 0.0001% Fluoro-Jade
C (in 0.1% acetic acid) for 25 min at RT, washed 362 min in
H2O with the last washing step containing 5 mM Hoechst 33342
(Molecular Probes) for nuclear staining, and finally sealed with
DPX mounting medium (Sigma).
Microscopy and Image Analysis
For the Hoechst/propidium iodide (PI) staining, coverslips with
primary cells from rat mixed cortical cultures were incubated in
5 mM PI (Sigma) and 5 mMHoechst 33342 (Molecular Probes) for
30 min at room temperature. Images were obtained on an
epifluorescence inverted microscope equipped with a 20x fluorite
objective (Olympus, Tokyo, Japan) using excitation light provided
by a Xenon arc lamp. Emitted fluorescence light was reflected
through a 380/10 nm filter (for Hoechst) or a 530 nm LP filter (for
PI) to a CCD camera (Retiga, QImaging, Canada). Each group
was done on 3 coverslips. Each coverslip was analysed on 4
pictures taken in randomly chosen areas using ImageJ software
(NIH, Bethesda, Maryland, USA).
Images of lentivirally transduced neuronal cultures were
acquired with a standard tissue culture epifluorescence microscope
with GFP filter set and 10x or 20x ADL objectives (Nikon) using
excitation light provided by an LED excitation light source. GFP-
positive cells were counted manually on the entire 13-mm
coverslip (for total number of green cells ,500) or from the
average of 7–10 randomly taken images of the 13-mm coverslip
and adjustment of the counted number to the total coverslip size
using the microscope’s unique field number (for total number of
green cells .500).
Images of double stained neuronal cultures were obtained on an
Axiovert AX10 microscope with FITC and Rhodamine filter sets
(Zeiss, Oberkochen, Germany), using a 10x Plan-Neofluar
objective and excitation provided by a HBO100 mercury light
source (Leistungselektronik, Jena, Germany). Overlay analysis was
done using Zeiss Axiovision software package.
Images of GFP-only positive brain sections were taken on an
Axiovert AX10 microscope with FITC filter set, using a 2.5x Plan-
Neofluar objective. Measurements of the size of the injection area
were done using ImageJ software. Sections of the entire rostro-
caudal length of the injection area were analysed for their two-
dimensional spread. The third dimension for the volumetric
analysis was added by applying the slice thickness (50 mm) as the
distance between sections and calculating the volume accordingly.
Images of double labelled brain slices, slices with staining of the
extracellular matrix and slices stained with Fluoro-Jade C were
acquired using the confocal laser scanning microscope Zeiss 710
LSM with a META detection system (Zeiss). A 20x objective was
used. HoechstH dye fluorescence was produced with the 405 nm
laser, GFP fluorescence using the 488 nm laser, and red
fluorescence with the 561 nm laser. For analysis of NeuN/GFP
double-positive cells, overlay images of two slices in close
proximity to the centre of the injection have been analysed per
animal using Volocity Demo software (Perkin Elmer, Waltham,
Massachusetts, USA).
Statistical Analysis
Statistical analysis was done using Origin 8.5 software (Microcal
Software Inc., Northampton, Massachusetts, USA). Data are
presented as mean 6 SEM. Data were compared by Student’s t-
test (two-tailed) or analysis of variance (ANOVA), followed by
Tukey post-hoc test, if appropriate. Statistical significance was
accepted if P,0.05.
Results
Transduction Efficiency Decreases with Age of the
Culture
To systematically investigate the relationship between DIV and
transduction efficiency, neuronal cultures (105 cells per well; N
= 3 per group) were transduced at different time points after
Hyaluronidase Facilitates Neuronal Transduction
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plating, (DIV 0 immediately after plating; DIV 2 and DIV 4, day 2
and day 4 after plating, respectively) with pGIPZ lentiviral vectors
at MOI = 3. The total number of GFP-positive cells was assessed
under the microscope seven days after transduction (Fig. 1). The
transduction efficiency as observed from the number of green cells,
decreased gradually, but significantly from DIV 0 (78726490) to
DIV 4 (11796109; one-way ANOVA, F2,6 = 92.3, P= 0.00003).
Hyaluronidase has a Dose Dependent Toxicity on Primary
Neurons which is Age Dependent
There is evidence that HA promotes neuronal survival, which
may be reduced by hyaluronidase treatment. To evaluate the
toxicity of hyaluronidase treatment neuronal cell cultures of
different ages (DIV 5, 8, 12) were incubated with a range of
concentrations of hyaluronidase (0 U/ml –300 U/ml) in the
growth medium (complete Neurobasal-A). After 3 or 7 days, the
viability of cells was determined with PI/DAPI staining (N= 3 per
group; Fig. 2A for timeline, 2C for example pictures). The two
lower concentrations (10 and 30 U/ml) did not show any
difference compared to control conditions (0 U/ml), with the
means of % PI-positive cells for 0 U/ml being 7.5361.76% on
DIV 5 (10 U, P= 0.99; 30 U, P= 0.87), 11.7461.7% on DIV 8
(10 U, P= 0.90; 30 U, P= 0.80) and 26.1263.11% on DIV 12
(10 U, P= 0.99; 30 U, P= 0.97). The highest concentration
(300 U/ml) resulted in high levels of PI-positive cells for all DIVs
(76.2–95.6%), while 100 U/ml was toxic for DIV 5 (P= 0.00003)
and DIV 8 (P= 0.0029) neuronal cultures with 62.7568.37% and
24.762.95% PI-positive cells respectively. For DIV 12 cultures
there was no difference to control (P = 0.45). Two-way ANOVA
(DIV, hyaluronidase concentration) analysis, followed by Tukey
post-hoc tests confirmed a significant effect of DIV (F2,45 = 7.7,
P = 0.001), hyaluronidase concentration (F4,45 = 191.0, P,10
28)
as well as the interaction between hyaluronidase concentration
and DIV (F8,45 = 10.1, P= 6.5*10
28). To test for possible side
effects of hyaluronidase treatment at a later time point, DIV 5
treated cells were also investigated 8 days after treatment. This
revealed essentially the same pattern as found on DIV 12, with 10,
30 and 100 U/ml resulting not in more PI-positive cells than
control (P = 0.61; Fig. 2B).
Based on these findings, in the following experiments, the two
lower concentrations 10 U/ml and 30 U/ml, which did not
produce significant toxic effects, were chosen to investigate effects
on transduction.
Hyaluronidase Improves Transduction Efficiency for
Neuronal Cultures DIV 5 - DIV 12
Transduction of neuronal cultures (105 cells per well; pGIPZ
vector) was carried out with different concentrations of hyaluron-
idase (0, 10 and 30 U/ml) added to the transduction medium
(complete Neurobasal-A). The number of green cells was assessed
seven days after transduction (Fig. 3A for timeline, Fig. 3B for sample
pictures). Detailed analysis revealed (Fig. 3C) forMOI= 1 that there
was a significant increase in number of transduced cells which
depended on hyaluronidase concentration (F2,26 = 57.7,
P= 1.5*1028) as well as age of the cultures (DIV, F2,26 = 7.4,
P= 0.005; two-way ANOVA (DIV, hyaluronidase)). Similar results
were obtained using a larger amount of vector (MOI 2), with
hyaluronidase concentration increasing (F2,26 = 42.2, P= 1.6*10
27)
and age of culture reducing (F2,26 = 13.7, P= 0.0002) efficiency of
transduction (N= 3 per group).
Hyaluronidase Improves Transfection with
Lipofectamine2000TM
Hyaluronidase may improve transduction efficiency by facili-
tating the access to the outer cellular surface for the DNA carrier
particles. Alternatively, it may have a function which is restricted
to lentivirus, for example by increasing the affinity of unique
surface properties specific for viral vectors. To rule out a viral
specific mechanism, a standard Lipofectamine2000TM transfection
of neuronal cultures with pCDH1-MCS1-EF1-copGFP was
analysed. The average size of Lipofectamine2000TM particles
carrying the DNA are between 160–410 nm diameter [31], and
thus slightly larger than the average size of lentiviral vectors (75–
100 nm) [32]. However, if hyaluronidase improves access to the
cell membrane by increasing the permeability of the ECM, it may
be expected to have an effect on other particles even if slightly
larger.
Cells were seeded at a density of 105 cells per well, and
Lipofectamine2000TM transfection was carried out on DIV 8
(N= 4 per group). The number of green cells was counted 10 days
after transfection (Fig. 4). At both low (0.8 mg), and high (1.6 mg)
DNA concentrations, treatment with 10 U/ml hyaluronidase
significantly increased the efficiency of transfection (1188645
versus 113625 green cells per well for 0.8 mg DNA (P,1028) and
1106654 versus 128612 green cells per well for 1.6 mg DNA
(P,1028). One-way ANOVAs (treatment) confirmed significant
differences between treatments for low DNA amount
(F2,11 = 285.3, P,10
28) and high DNA amount (F2,11 = 212.8,
P= 2.6*1028). Treatment with enzyme for 1 hour was more
effective than 24 hour treatment, however 24 hour treatment was
still significantly higher than control (451623 green cells per well
for 0.8 mg DNA, P=1.5*1025, and 442621 green cells per well
for 1.6 mg DNA, P=4.0*1025; Tukey post-hoc tests).
Hyaluronidase Increases the Percentage of Transduced
NeuN-positive Neurons in vitro
In order to verify that the improvement in transduction
efficiency was not restricted to increase in transduction of non-
neuronal cells in our mixed cultures, we also assessed the
Figure 1. Transduction efficiency decreases with increased age
of neuronal culture. Primary neuronal cultures were transduced at
DIV 0 - DIV 4 with pGIPZ vector (MOI = 3), revealing decreased
transduction efficiency with increasing age of the culture (N= 3 per
group). *** P,0.001.
doi:10.1371/journal.pone.0053269.g001
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proportion of transduced cells which were positive for NeuN,
a neuronal marker. Primary neuronal cultures were transduced on
DIV 12 with the third generation pCDH1-MCS1-EF1-copGFP
lentiviral vector at MOI= 30, applying 0, 10 or 30 U/ml
hyaluronidase (N=3 per group), and the number of green cells
per well was assessed seven days after transduction (Fig. 5B). This
relatively high MOI was chosen in order to produce conditions
which are comparable to the situation in vivo, where locally high
amounts of virus accumulate due to restricted diffusion within the
target tissue from the injection needle. For the estimation of an
approximate MOI we considered the cerebral cortex to contain
around 0.5–1 * 105 neurons per mm3 [33], and an injection of 2 *
106 TU of lentiviral vectors (e.g. 2 ml of vector with a titre of 1 *
109 TU/ml), which is expected to spread approximately 1 mm3
around the injection site. Altogether, this would result in an MOI
of approximately 20–40 in total for neurons at the injection site.
Under these conditions, the transduction efficiency of NeuN-
positive cells increased from 63.465.3% (control) to 72.565.3%
(10 U/ml) and 84.565.3% (30 U/ml), as confirmed by one-way
ANOVA (F2,8 = 11.8, P= 0.008; Fig. 5A).
Toxic Effects Occur in vivo after Treatment with High
Concentrations of Hyaluronidase
In order to visualise potentially toxic effects of intracerebral
hyaluronidase injections, brains which received PBS, 4, 20, or
40 U hyaluronidase (or 4 mg kainic acid as a positive control)
treatment, were perfusion-fixed 24 h after injection, and pictures
of the Fluoro-Jade C-stained sections were taken. These images
included the injection canal, the area where the hyaluronidase is
expected to be at the highest concentration (Fig. 6). In all
conditions, a small number of positive cells were visible, including
PBS injection and injection of 4 U hyaluronidase. These positive
(green) cell bodies were distributed within the area near the canal,
but they were also apparent at some distance. In contrast 20 U
produced slightly more positive cells, while 40 U resulted in a large
number of green cells focused on the area immediately surround-
ing the injections site. Staining from injections containing 20 U
hyaluronidase was similar to the effects of an injection of kainic
acid, which is neurotoxic and which served as a positive control.
Figure 2. Toxicity of hyaluronidase in vitro is dependent on dose and age of neuronal cultures. (A) Experimental timeline. For each row,
treatment refers to the point at which hyaluronidase was added, and analysis indicates when cells were assessed for toxicity. DIV5– late cells were
treated with hyaluronidase at the same time as DIV 5 cells but were allowed to recover for longer. (B) Three days after treatment with hyaluronidase,
PI/Hoechst staining of neuronal cultures revealed increased cell death at 100 U/ml and 300 U/ml for DIV 5 and DIV 8 cultures, while 100 U/ml did not
produce any difference to control level for DIV 12 cells. Allowing cells treated on DIV 5 to recover for 7 days after treatment (DIV 5 - late) showed toxic
effects only for 300 U/ml, revealing that potential damage of 100 U/ml is transient. *** p,0.001, ** p,0.01, n.s. not significant, compared to 0 U/ml
respectively (ANOVA) (C) Representative images of hyaluronidase (10 U/ml) treated cells with PI and Hoechst staining. (N = 3 per group). Scale
bar = 10 mm;
doi:10.1371/journal.pone.0053269.g002
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Local Injection of Hyaluronidase Produces Local
Degradation of Extracellular Matrix
For the investigation of the size of the area where the ECM is
being degraded, the lower dose of 4 U was chosen because it
appears to be less toxic than 20 U with Fluoro-Jade C staining.
Brains were analysed 24 h after injection using Wisteria floribunda
agglutinin (WFA)/Streptavidin-TexasRed (WFA), which binds to
components of the ECM, and was used to reveal the degradation
of ECM, because direct staining of digested hyaluronan in adult
brain is not possible [34]. As expected, staining with WFA
revealed robust ECM signal across the whole brain section
indicated by a red staining between blue (HoechstH dye) nuclei,
and with occasional very high density signals around few selected
cells. Injection of 4 U of hyaluronidase produced a clearly visible
area lacking ECM signal as a result of the hyaluronidase activity.
This area was located slightly below the needle track, consistent
with restricted area of hyaluronidase activity. The size of the area
affected by hyaluronidase was variable, and the edges were too
diffuse to allow exact quantitative analysis, however the largest
extent of the diffusion area was in the range of 500–1000 mm in
diameter, which would result approximately in a spherical volume
of 0.1–0.5 mm3 (Fig. 7).
Intracerebral Injections of Lentiviral Vectors to Assess
Effects of Hyaluronidase in vivo
A concentrated lentiviral vector stock solution of pCDH1-
MCS1-EF1-copGFP (2 * 109 TU/ml) was mixed 1:1 with PBS or
hyaluronidase/PBS (4 or 20 U/ml), and 2 ml of this mixture was
injected into the motor cortex of 11-week old rats, resulting in
Figure 3. Hyaluronidase increases transduction efficiency of neuronal cultures with higher DIV. (A) Experimental timeline as for Figure 2,
except that treatment and transduction occurred at the same timepoint (B) The two non-toxic doses 10 and 30 U/ml showed robustly improved
transduction efficiency on neuronal cultures. (C) For the two different MOIs studied, the improved transduction efficiency under Hyaluronidase
treatment appeared more pronounced for younger cultures (N = 3 per group; statistics in text). Scale bar = 20 mm.
doi:10.1371/journal.pone.0053269.g003
Figure 4. Transfection efficiency of neuronal cultures is
increased when preceded with Hyaluronidase treatment.
Neuronal cultures were transfected with Lipofectamine2000TM and
two different amounts of DNA (0.8 and 1.6 mg DNA), resulting in similar
transfection efficiencies, with both transfections strongly enhanced by
hyaluronidase treatment. Pretreating cultures 1 h before transfection
was more effective than treatment 24 h before transfection. (N= 4 per
group) ***p,0.001, compared to 0 U/ml respectively.
doi:10.1371/journal.pone.0053269.g004
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106 TU vector and 0, 4 or 20 U hyaluronidase per site. Analysis of
the total volume of spread as judged from the GFP-positive area
on consecutive brain slices indicated that there was no difference
in size of the GFP-positive area with 0.3860.08 mm3 for PBS
(N= 7), 0.3860.05 mm3 for 4 U (N=4) and 0.3860.09 for 20 U
hyaluronidase (N= 3), (P = 0.99; one-way-ANOVA; Fig. 8A).
Analysing the proportion of NeuN-positive cells however revealed
that there was a significant difference with 54.965.7% for 20 U,
51.963.7% for 4 U and 35.662.8% for PBS of NeuN cells being
transduced with lentiviral vector (F2,11 = 8.7, P= 0.005; one-way
ANOVA; Fig. 8B).
Figure 5. Hyaluronidase increases the percentage of NeuN-positive cells being transduced at high MOI, mimicking an in vivo
situation with high MOI surrounding the injection site. (A) Hyaluronidase increases the percentage of transduced NeuN-positive cells. (B)
Representative images and overlay. Closed circle represents transduced NeuN-positive cell, dashed circle indicates non-transduced NeuN-positive cell
(N = 3 per group). Scale bar = 20 mm.
doi:10.1371/journal.pone.0053269.g005
Figure 6. Toxicity of Hyaluronidase in vivo. Fluoro-Jade C staining (green, bottom panel) overlaid with Hoechst (blue) reveals differing levels of
toxicity after injecting different amounts of hyaluronidase. Compared to PBS control, 4 and 20 U/site showed little or no increase in toxicity for cells
around the injection site. In contrast, 40 U hyaluronidase is of a similar extent to kainic acid (4 mg/site), which served as positive control for the
staining Pictures were taken from areas surrounding the cannula tract, which is outlined in red. Scale bar = 100 mm.
doi:10.1371/journal.pone.0053269.g006
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Discussion
To obtain optimal gene therapy with viral vectors it is important
to obtain the best possible transduction efficiency, and to be able to
modify the desired subset of cells. In some tissues this presents
more of a challenge than in others, and in many circumstances,
mature neurons are difficult to transduce. Even before viral gene
therapy emerged as a means for delivering genetic material to
cells, it was known that chemical agents, in particular polycations
like polybrene, DEAE-dextran or poly-1-ornithin could enhance
viral infectivity [35,36]. However, the practical use of these agents
is limited due to their toxicity. We show that hyaluronidase
treatment also improves the efficiency of viral transduction of
neurons with lentiviral vectors both in vitro and in vivo, and can be
effective at low concentrations which are not toxic. Importantly,
hyaluronidase treatment increases the percentage of transduced
cells positive for NeuN, which is a marker for mature post-mitotic
neurons [37]. These cells are often the primary target cells in
potential applications of gene therapy in neurosciences and are
expected to be a major target of gene therapy in clinical neurology.
Hyaluronidase has already been shown to be effective in
improving transduction in other tissues, such as studies using anti-
tumour retroviruses in cellular pleura models [38], improvement
of activity of oncolytic adenoviruses in a mouse tumour model
[39], or increased administration of AAV into skeletal muscle [40].
Previous studies of hyaluronidase in the CNS have shown it can
increase the distribution of nanoparticles (54 nm diameter), when
the particles are injected into rat brain after hyaluronidase
treatment [41]. In that study the size of the target area was
increased by about 56%. In contrast, we did not see an increased
distribution of the viral particles, which could reflect the smaller
size of the nanoparticles compared to lentiviral particles, the
different brain region targeted (striatum, as opposed to motor
cortical area), the more homogeneous distribution of nanoparticles
due to their smooth surface (as opposed to that of lentiviral vector
particles, containing proteins), or the higher volume and amount
of enzyme used in the nanoparticle study (5 ml of 20000 U/ml,
which resulted in a total amount of 100 U injected, as opposed to
4 U in 2 ml per site used in our study). However, our in vivo results
on toxicity indicate that 40 U produces significant toxicity, which
might confound the goal of gene therapy. It is important to note
that in vivo the distribution volume and local concentration of
hyaluronidase are not easy to quantify and there may be
a substantial concentration gradient of the injected enzyme
between the centre of injection and the diffusion edges.
Abordo-Adesida et al. demonstrated that in vivo there is a satu-
ration effect for transduction, with the transduction efficiency not
changed as the number of particles injected increased from 106
to107 particles per site [42]. One possibility is that disrupting the
extracellular matrix with hyaluronidase would overcome this
barrier, allowing surplus particles to reach more distant target
neurons. However, we did not see an increase in the size of the
Figure 7. Effects of hyaluronidase on ECM in vivo. 24 h after Injection of PBS (top row) or 4 U hyaluronidase (bottom row), ECM staining with
WFA/Streptavidin-TexasRed was done. This revealed a distinct area of degraded ECM underneath the cannula tract for 4 U hyaluronidase. Images in
leftmost column are lower magnification for overview, scale bar = 250 mm. Right columns are detailed view of the white inserts, scale bar = 100 mm.
doi:10.1371/journal.pone.0053269.g007
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target area in the presence of hyaluronidase. Instead our data
indicated the enzyme increased the proportion of neurons within
the targeted area that were positive for GFP, suggesting the
enzyme enhanced access to these cells. If the extracellular matrix
plays an important role in restricting viral tropism, then mature
neurons, with a rather rigid and less permeable extracellular
matrix, would be predicted to be more difficult to transduce than
cells with less dense ECM. This is consistent with what we saw
in vitro, where the beneficial effect of hyaluronidase treatment
gradually declined from DIV 5 to DIV 12, possibly reflecting the
meshwork increasing around neurons and finally make up the
PNNs together with other components that are not subject to
cleavage by hyaluronidase. Glial cells and neurons have both been
implicated in building up ECM material and PNNs [43,44]. It has
been shown that between week 2 and 3 in vitro cultures start to
build up the ECM which is similar to that of the adult brain and
mainly based on HA and chondroitin sulphate proteoglycans,
[45]. This time window also coincides with our observation that
hyaluronidase treatment is effective at improving transduction
efficiency during the second week in vitro.
Hyaluronidase also improved transfection efficiency of neurons
using a standard transfection protocol using Lipofectami-
ne2000TM. This suggests that the improvement in efficiency is
not specific to lentiviral particles but may be a direct result of
making the cell surface more accessible to particles larger than the
pores in the intact ECM. In untreated cells the ECM is described
to create a network with pores as small as 56 nm [46]. These pores
would effectively exclude, lentiviral particles (70–100 nm diameter
[32]) and Lipofectamine2000TM particles (160–410 nm [31]) from
reaching the surface of cells. Increased accessibility by degrading
the network of ECM may be sufficient to allow larger particles to
reach and interact with the cell membrane.
Hyaluronidase could potentially have off-target effects that
would limit its use. The hyaluronidase used in this study was
isolated from bovine testes and cleaves the 1–4 linkage between N-
acetylglucosamine and D-glucuronic acid randomly within the HA
Figure 8. In vivo stereotactic injection into rat cortex of pCDH1-MCS1-EF1-copGFP lentiviral vector does not result in wider
spreading, but in an increased percentage of transduced NeuN-positive cells. (A) Volumetric analysis of the injection site revealed no
difference between PBS, 4 or 20 U hyaluronidase (HYA). Inserts with rat brain images were taken from [49]. Scale bar = 400 mm (B) Percentage of GFP/
NeuN-positive cells is increased after co-injection of viral vector and hyaluronidase. *p,0.05; Scale bar = 100 mm.
doi:10.1371/journal.pone.0053269.g008
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macromolecule. It also cleaves analogous molecular bonds within
the macromolecules chondroitin, chondroitin-4- and -6-sulfates,
and dermatan. However, these molecules form part of the
extracellular matrix with primarily scaffolding function and, thus,
their cleavage is more likely a synergistic by-phenomenon than
a drawback for our application.
In gene therapy trials, it will be important to have a delivery
mechanism which does not cause toxicity to the target cells. Our
data indicate that hyaluronidase, at the doses we used may have
no or limited side effects (as seen in vitro from the PI/Hoechst
staining for doses 10 and 30 U/ml, Fig. 2; and in vivo from Fluoro-
Jade C staining for doses 4 and 20 U, Fig. 6), and, does not have
long-lasting effects (due to the reversibility of the facilitating effect
24 h after hyaluronidase treatment, Fig. 4). These data suggest at
the concentrations we used hyaluronidase is not toxic to neurons.
In addition even the toxicity measurement of DIV5 treated cells at
the later time point (day 7 after treatment; Fig. 2) is reassuring that
no long lasting consequences arise from the one-off treatment.
The unique properties of lentiviral vectors, in particular their
large gene packaging capacity and their ability to transduce post-
mitotic cells like neurons, make them ideal tools to use for gene
therapy in neurosciences, even more in conjunction with the
advent of non-integrating lentiviral vectors [47,48], which have
a highly improved safety profile in terms of insertional mutagenesis
of the host cell genome. Improving their efficiency for transducing
neurons is a major goal, and our data suggest that co-
administration of lentiviral vectors with hyaluronidase may be
one step towards making gene therapy more effective in the central
nervous system.
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